Table 6

	Treatment Subgroups (Male)		Treatment Subgroups (Female)
Week	AML	HCZ	AML	HCZ	Gender Effect
0	172.90 ± 1.95	173.70 ± 2.90	169.20 ± 2.84	169.80 ± 2.92	0.0004***
1	172.60 ± 2.02	173.50 ± 2.89	169.10 ± 2.76	169.90 ± 2.92
3	172.00 ± 2.15	174.00 ± 2.87	168.50 ± 2.80	170.70 ± 3.04
6	170.00 ± 2.03	175.60 ± 2.88	167.40 ± 2.66	171.80 ± 2.94
12	168.50 ± 2.08^b	177.00 ± 2.94^a	165.90 ± 2.58	172.50 ± 2.92
24	167.90 ± 2.04^b_A	178.20 ± 2.97^a	165.90 ± 2.70^b	173.50 ± 2.95^a
36	167.40 ± 2.09^b_A	178.40 ± 2.91^a	165.60 ± 2.72^b	173.00 ± 3.05 ^a
48	167.40 ± 2.06^b_A	178.10 ± 2.92^a	165.40 ± 2.59^b	173.00 ± 3.05^a

Table 6: Effects of monotherapy with AML and HCZ on low density lipoprotein cholesterol (mg/dl) in diabetic hypertensive subjects for 48 weeks.